ST. LOUIS PARK, Minn.--(BUSINESS WIRE)--NeoChord, Inc., a leader in advancing the treatment of minimally invasive repair of degenerative mitral valve regurgitation (DMR) without the use of cardiopulmonary bypass, today announced that David H. Adams, MD, and Michael A. Borger, MD, PhD, will serve as national co-principal investigators of the company’s US pivotal trial scheduled to commence later this year. “NeoChord is very fortunate to have the leadership of two world-renowned surgeon-scientists directing the clinical investigation of the NeoChord DS1000 system,” said David Chung, President and CEO of NeoChord.
Dr. Adams is the Marie-Josée and Henry R. Kravis Professor and Chairman of the Department of Cardiovascular Surgery in the Icahn School of Medicine at Mount Sinai, and Cardiac Surgeon-in-Chief of the Mount Sinai Health System. An acclaimed speaker, author, and renowned educator in the field of mitral valve reconstruction, Dr. Adams has given more than 350 invited lectures, authored more than 250 publications, and performed mitral valve surgery throughout the world. Over the past several years he has served as the National Co-Principal Investigator of the Medtronic CoreValve US Pivotal Trial. He is also a co-author with Professor Alain Carpentier of the world’s widest selling textbook in mitral valve reconstruction.
Dr. Borger is Professor of Cardiothoracic Surgery at Columbia Presbyterian School of Medicine, and the Director of Aortic Surgery at the Cardiovascular Institute in the New York-Presbyterian/ Columbia University Medical Center. Previously, he served as Professor and the Associate Director of the Leipzig Heart Center, the largest heart valve center in Europe. Dr. Borger is an internationally recognized leader in the fields of minimally invasive cardiac surgery, aortic surgery and novel surgical approaches to treat valvular heart disease. On the forefront of pioneering strategies to advance cardiac surgery throughout his career, he has published 250 contributions on a wide range of topics and served in numerous societal and academic journal leadership positions in both Europe and North America.
“To date, the NeoChord technology has demonstrated excellent outcomes from its commercial experience in Europe,” stated Dr. Adams. “I look forward to partnering with Dr. Borger as we initiate the U.S. pivotal trial for this cutting-edge technology.”
Summarizing the enthusiasm of the NeoChord Board of Directors, Chung expressed, “Throughout their careers, Dr. Adams and Dr. Borger have demonstrated a passion for taking innovative technologies from early design to integration into clinical practice; we are very excited to announce this collaboration for our upcoming FDA trial.”
About NeoChord, Inc.
Based in St. Louis Park, Minn., NeoChord, Inc. is a privately held medical technology company leading the advancement of minimally invasive repair of DMR. Mitral regurgitation is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated. NeoChord received CE market clearance in December 2012 for the DS1000 system for minimally invasive mitral valve repair of degenerative mitral regurgitation without the use of cardiopulmonary bypass. To date, over 350 patients have been treated. For more information, visit: www.NeoChord.com.
The NeoChord DS1000 System is CE marked and approved for sale in
CAUTION: The NeoChord device is not available for use in the United States.